Evidence to support 'breakthrough' drugs often very limited: study

(Reuters Health) - The 46 medicines given approval through 2017 as part of the U.S. Food and Drug Administration's Breakthrough Therapy program have often been sent to patients without a large double-blind study, direct measurement of benefit, or comparison with a placebo or existing treatment, according to a new analysis by researchers at Yale University and the Yale School of Medicine.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news